Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization by Sánchez-López, E. (Elena) et al.
Sánchez‑López et al. J Nanobiotechnol  (2018) 16:32 
https://doi.org/10.1186/s12951‑018‑0356‑z
RESEARCH
Memantine loaded PLGA PEGylated 
nanoparticles for Alzheimer’s disease: in vitro 
and in vivo characterization
Elena Sánchez‑López1,2,3*, Miren Ettcheto3,4, Maria Antonia Egea1,2, Marta Espina1,2, Amanda Cano1,2,3, 
Ana Cristina Calpena1,2, Antoni Camins3,4, Nuria Carmona1, Amélia M. Silva5,6, Eliana B. Souto7,8 
and Maria Luisa García1,2
Abstract 
Background: Memantine, drug approved for moderate to severe Alzheimer’s disease, has not shown to be fully 
effective. In order to solve this issue, polylactic‑co‑glycolic (PLGA) nanoparticles could be a suitable solution to 
increase drug’s action on the target site as well as decrease adverse effects. For these reason, Memantine was loaded 
in biodegradable PLGA nanoparticles, produced by double emulsion method and surface‑coated with polyethylene 
glycol. MEM–PEG–PLGA nanoparticles (NPs) were aimed to target the blood–brain barrier (BBB) upon oral administra‑
tion for the treatment of Alzheimer’s disease.
Results: The production parameters were optimized by design of experiments. MEM–PEG–PLGA NPs showed a 
mean particle size below 200 nm (152.6 ± 0.5 nm), monomodal size distribution (polydispersity index, PI < 0.1) and 
negative surface charge (− 22.4 mV). Physicochemical characterization of NPs confirmed that the crystalline drug was 
dispersed inside the PLGA matrix. MEM–PEG–PLGA NPs were found to be non‑cytotoxic on brain cell lines (bEnd.3 
and astrocytes). Memantine followed a slower release profile from the NPs against the free drug solution, allowing to 
reduce drug administration frequency in vivo. Nanoparticles were able to cross BBB both in vitro and in vivo. Behavio‑
ral tests carried out on transgenic APPswe/PS1dE9 mice demonstrated to enhance the benefit of decreasing memory 
impairment when using MEM–PEG–PLGA NPs in comparison to the free drug solution. Histological studies confirmed 
that MEM–PEG–PLGA NPs reduced β‑amyloid plaques and the associated inflammation characteristic of Alzheimer’s 
disease.
Conclusions: Memantine NPs were suitable for Alzheimer’s disease and more effective than the free drug.
Keywords: Memantine, Nanoparticles, Alzheimer’s disease, Brain targeting, APPswe/PS1dE9 mice, β‑Amyloid 
plaques, bEnd.3, Astrocytes
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Background
Alzheimer’s disease (AD) is the most prevalent neuro-
degenerative disorder amongst patients over 65  years 
old [1]. Memantine hydrochloride (MEM), a low-affinity 
voltage-dependent uncompetitive antagonist to gluta-
matergic N-methyl-d-aspartate (NMDA) receptors, is 
the only drug approved both in Europe and in the United 
States for moderate and severe degrees of the disease.
The clinical applications of nanoparticles (NPs) have 
proven great advantages for targeting and drug deliv-
ery, in particular, for the management of AD since cur-
rent therapeutic strategies are compromised by the tight 
junctions and endothelial cells of the blood–brain-barrier 
(BBB) [2]. Nanoparticles, with an average size below 
200 nm, may represent an alternative for prolonged drug 
delivery across the BBB, given their capacity for endo-
cytic transport [3, 4]. While a number of polymers have 
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already been used in the production of NPs, polyesters 
such as poly d,l-(lactic-co-glycolic) acid (PLGA), have 
been extensively applied for controlled drug delivery, 
including brain targeting [5, 6]. PLGA, which has been 
approved by the Food and Drug Administration, is one 
of the most successful biodegradable polymers because it 
undergoes hydrolysis to produce lactic and glycolic acid, 
easily cleared from the body [7]. In addition, advanced 
drug delivery systems based on PLGA NPs have recently 
demonstrated to be potential alternatives for the treat-
ment neurodegenerative diseases [8]. A limitation on the 
use of PLGA NPs in drug delivery is, however, their fast 
uptake and clearance from the reticuloendothelial system 
(RES). To overcome the RES clearance, surface coating of 
NPs with poly (ethylene glycol) (PEG) has been recom-
mended, an approach that has demonstrated to reduce 
NPs’ clearance significantly in vivo [9]. In addition, it has 
also been proven that such surface coating may increase 
NPs targeting and uptake through the BBB [10]. Load-
ing drugs in PEG-PLGA NPs with a matrix structure is 
expected to prolong their circulation half-life compared 
to non-coated PLGA NPs, due to the presence of mobile 
and flexible PEG chains on their surface.
Memantine (MEM) is a good candidate for drug load-
ing. MEM is an uncompetitive (open-channel) NMDA 
receptor antagonist with low-to-moderate affinity, which 
binds preferentially to the NMDA receptor-operated 
cation channels, overlapping the site of Magnesium [11]. 
Therefore, MEM decreases the excessive glutamate which 
causes neuronal death on AD patients [11]. Although this 
drug was found to improve patients’ cognition, global 
functioning behaviour and stage of dementia in com-
parison to placebo groups, results obtained from meta-
analysis of AD monotherapy translate its limited clinical 
benefits (i.e. the assessment scores were not statistically 
significant between treated and non-treated groups) [12]. 
In this sense, drug delivery systems would increase drug 
concentration on the target site probably enhancing it’s 
effects against AD. In addition, despite being well-toler-
ated, MEM requires daily administration by the patients 
which, combined with the poor drug compliance, may 
also reduce the rates of successful treatment.
A sustained release formulation, based on PLGA NPs 
for oral administration, has been proposed to assure that 
the drug remains on the target site until the next patients’ 
intake of the medicine. MEM–PEG–PLGA NPs are 
expected to contribute to a time-stable dose on the brain, 
prolonging drug release, reducing administration fre-
quency and decreasing the adverse-side effects. Compar-
ing to other routes, and for chronic treatment schedules, 
oral administration offers comfort and improves patient’s 
compliance. Recent studies have demonstrated the 
added-value of loading drugs in PLGA NPs to enhance 
their oral bioavailability [13, 14]. PEG surfacing PLGA 
NPs have enhanced mucus permeating properties, there-
fore contributing to increase the drug’s bioavailability 
after oral administration [15].
In the present work, we report the development of 
a physicochemical stable, sustained-release MEM–
PEG–PLGA NPs formulation, for the treatment of AD. 
Developed MEM–PEG–PLGA NPs are reported to be a 
non-invasive approach for brain targeting of MEM, with 
minimal adverse-side effects. The physicochemical stabil-
ity of MEM after loading in PLGA NPs has been char-
acterized by drug-polymer interaction studies, and by 
in vitro release profile. Cell viability was studied and the 
in  vitro transport across the BBB was mapped. Trans-
genic and non-transgenic mice were orally treated with 
MEM–PEG–PLGA NPs and compared with the results 
obtained after treatment with free drug solution. Brain 
and plasma drug concentrations were measured, whilst 
behavioural test and histological studies were undertaken 
to elucidate the therapeutic efficacy of MEM–PEG–
PLGA NPs against free drug, for brain delivery.
Methods
Materials
PLGA-PEG  Resomer® RGP d 5055 was obtained from 
Boehringer Ingelheim, Germany and memantine (MEM) 
was purchased from Capotchem (Hangzhou, China). 
Water filtered through Millipore MilliQ system was used 
for all the experiments and all the other reagents were of 
analytical grade.
Production and physicochemical characterization 
of nanoparticles
MEM loaded NPs were produced by a modified double 
emulsion method described elsewhere [16, 17]. Briefly, a 
predetermined amount of PLGA–PEG was dissolved in 
ethyl acetate (EA) forming the organic phase. Aqueous 
phase  (w1) was obtained by dissolving MEM in deionized 
water. Sonication energy was applied to form the primary 
emulsion  (w1/o). The  w1/o emulsion was then dispersed 
in 2  ml of deionized water containing PVA. Secondary 
emulsion  (w1/o/w2) was formed with ultrasound energy 
[18]. A volume of 2 ml of PVA (0.3%) were then added, 
under magnetic stirring, to stabilize the colloidal sys-
tem. Solvent was evaporated and NPs were washed by 
centrifugation at 15,000 r.p.m. during 20 min. The load-
ing of NPs with rhodamine followed the same procedure. 
Empty NPs were prepared using the same approach but 
without addition of drug into the inner water phase [19].
Mean average size (Z-AVE) and polydispersity index 
(PI) of NPs were determined by photon correlation 
spectroscopy (PCS) using a ZetaSizer Nano ZS (Mal-
vern Instruments). Measurements were carried out by 
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triplicate at 180° in 10 mm diameter cells at a tempera-
ture of 25  °C. Zeta potential (ZP) was calculated from 
electrophoretic mobility as described elsewhere [20, 21].
Drug concentration was determined indirectly. Pre-
viously to the analysis, the non-loaded drug was sepa-
rated from NPs by filtration/centrifugation at 14,000 
r.p.m. (Mikro 22 Hettich Zentrifugen, Germany) using an 
 Amicon® Ultra 0.5 centrifugal filter device (Amicon Mil-
lipore Corporation, Ireland). The encapsulation efficiency 
(EE) was calculated by the difference between the total 
amount of drug and the free drug, present in the filtered 
fraction, using Eq. (1):
The quantification of MEM was performed in multi-
ple reaction monitoring (MRM) mode using an ion trap 
mass spectrometer equipped with an atmospheric pres-
sure electrospray ionization ion source, positive mode. 
The HPLC system was an Agilent 1100 series (Agilent 
Technologies, USA) coupled with a Brucker Ion Trap SL 
(Brucker Daltonics GmbH, Germany). MEM was sepa-
rated on a reversed phase column (Kinetex de 2.6  μm 
50 × 2.1 (Phenomenex) using methanol 0.1% formic acid 
in water 55:45 (v/v) as mobile phase. The flow rate was 
1 ml/min at 45 °C [22].
(1)EE(%) =
Total amount of MEM− Free MEM
Total amount of MEM
Design of experiments
Design of experiment (DoE) was used to optimize the 
developed formulation. Series of independent param-
eters and their influence on NPs properties were studied, 
determining the effects and interactions between factors. 
The effect of a factor × (Ex), was calculated using Eq. (2):
where ∑X(+) stands for the sum of the factors at their 
highest level (+ 1), ∑X(−) is the sum of the factors at 
their lowest level (−1), and n/2 is the half of the number 
of measurements. Interactions between factors (factor 1: 
factor 2) were also calculated. To estimate an interaction 
between two factors, the effect of the first factor at the 
lowest level of the second factor has to be calculated and 
subtracted it from the effect of the first factor at the high-
est level of the second factor.
For the study of the sonication parameters (Table  1) 
and concentration compounds (Table  2) two independ-
ent full factorial designs were performed. The mean size 
(Z-AVE), PI and ZP of the NPs were studied and the 
effects and interactions between factors were calculated. 
According to the composite design matrix generated by 
Statgraphics Plus 5.1 software, a total of 16 experiments 
(8 factorial points, 6 axial points and two replicated 
center points) were required for each design. The studied 
(2)Ex =
∑
X(+)−
∑
X(−)
n/2
Table 1 Values of the matrix of a factorial design of sonication parameters and measured responses
Italic values correspond to the optimized formulation of MEM loaded NPs
Amplitude 1st sonication time 2nd sonication time Zav (nm) PI ZP (mV) EE (%)
Coded level (%) Coded level (s) Coded level (s)
Factorial points
F1 − 1 25.0 − 1 20.0 − 1 120.0 390.4 ± 2.2 0.213 ± 0.039 − 6.73 ± 0.04 3.46
F2 1 35.0 − 1 20.0 − 1 120.0 249.7 ± 4.7 0.069 ± 0.022 − 6.33 ± 0.49 9.59
F3 − 1 25.0 1 40.0 − 1 120.0 184.6 ± 0.7 0.125 ± 0.023 − 6.43 ± 0.45 42.57
F4 1 35.0 1 40.0 − 1 120.0 227.0 ± 2.6 0.057 ± 0.019 − 6.72 ± 0.33 36.89
F5 − 1 25.0 − 1 20.0 1 240.0 243.0 ± 0.9 0.194 ± 0.012 − 6.72 ± 0.24 7.43
F6 1 35.0 − 1 20.0 1 240.0 248.1 ± 1.9 0.053 ± 0.037 − 6.48 ± 0.15 14.69
F7 − 1 25.0 1 40.0 1 240.0 258.7 ± 4.5 0.198 ± 0.011 − 6.35 ± 0.33 22.63
F8 1 35.0 1 40.0 1 240.0 206.4 ± 1.2 0.061 ± 0.045 − 6.67 ± 0.30 2.88
Axial points
F9 1.68 38.4 0 30.0 0 180.0 222.4 ± 2.4 0.033 ± 0.011 − 5.63 ± 0.37 39.12
F10 − 1.68 21.6 0 30.0 0 180.0 162.6 ± 0.4 0.262 ± 0.012 − 6.83 ± 0.37 39.36
F11 0 30.0 1.68 47.0 0 180.0 226.7 ± 4.4 0.236 ± 0.011 − 6.49 ± 0.25 19.94
F12 0 30.0 − 1.68 13.0 0 180.0 196.8 ± 2.5 0.103 ± 0.056 − 6.47 ± 0.55 43.10
F13 0 30.0 0 30.0 1.68 281.0 239.8 ± 0.7 0.056 ± 0.020 − 5.77 ± 0.47 23.39
F14 0 30.0 0 30.0 − 1.68 79.0 382.6 ± 5.2 0.221 ± 0.011 − 5.93 ± 0.21 33.95
Center points
F15 0 30.0 0 30.0 0 180.0 220.1 ± 5.6 0.059 ± 0.019 − 5.36 ± 0.03 24.01
F16 0 30.0 0 30.0 0 180.0 222.1 ± 3.6 0.062 ± 0.021 − 5.36 ± 0.11 23.23
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experimental responses were the result of the individual 
influence and the interaction of the three independent 
variables.
Nanospheres characterization and interaction studies
Morphology of the optimized formulation of MEM 
loaded NPs was determined by transmission elec-
tron microscopy (TEM), performed on a JEOL 1010 
microscope (Akishima, Japan). The physical state and 
chemical interactions between drug and polymers were 
studied by thermal and X-ray diffraction analyses. For 
the interaction studies, NPs were washed by centrifuga-
tion and dried to constant weight previous to carry out 
the analysis. MEM thermal properties were studied by 
thermogravimetric (TG) analysis and differential thermal 
analysis (DTA) on a TASC 414/3 (Netsch, Thermal Anal-
ysis). Temperature ranged from 25 to 600 °C at 10 °C/min 
and  AlO3 pan was used as a reference. All experiments 
were carried out under nitrogen flow. Thermograms 
were obtained by differential scanning calorimetry (DSC) 
on a Mettler TA 4000 system (Greifensee, Switzerland) 
equipped with a DSC 25 cell. Samples were weighed 
(Mettler M3 Microbalance) in perforated aluminium 
pans and heated under a flow nitrogen at a rate of 10 °C/
min. X-Ray diffraction (XRD) was used to analyse the 
amorphous versus crystalline status of the samples. Com-
pounds were sandwiched between polyester films and 
exposed to CuK” radiation (45 kV, 40 mA, λ = 1.5418 Å) 
in the range (2θ) from 2° to 60° with a step size of 0.026° 
and a measuring time of 200  s per step. Fourier-trans-
formed infra-red (FTIR) spectra of different compounds 
were obtained using a Thermo Scientific Nicolet iZ10 
with an ATR diamond and DTGS detector.
Storage stability
The stability of MEM–PEG–PLGA NPs stored at three 
different temperatures (4, 25 and 38  °C) was studied by 
light backscattering using  Turbiscan®Lab operated at 
constant temperature. For this purpose, a glass measure-
ment cell was filled with 20 ml of sample. The light source 
is a pulsed near infrared light and was received by a back-
scattering detector at an angle of 45° from the incident 
beam. Backscattering data were acquired once a month 
for 24 h at intervals of 1 h. In addition to this technique, 
morphometric parameters (Z-AVE, PI and ZP) were also 
measured.
In vitro drug release
In vitro drug release of MEM–PEG–PLGA NPs was stud-
ied against free MEM in PBS, in a bulk equilibrium direct 
dialysis bag technique under sink conditions for 36  h 
(n = 6). Briefly, a volume of 5 ml of each formulation was 
placed directly into a dialysis bag (cellulose membrane, 
12–14  kDa, size 3,20/32’’ diameter, Iberlabo) and each 
Table 2 Values of the matrix of a factorial design of concentration parameters and measured responses
Italic values correspond to the optimized formulation of MEM loaded NPs
c PLGA− PEG c MEM c PVA Zav (nm) PI ZP (mV) EE (%)
Coded level (mg/ml) Coded level (mg/ml) Coded level (mg/ml)
Factorial points
F1 − 1 10 − 1 3 − 1 2.5 270.0 ± 2.4 0.081 ± 0.002 − 13.4 ± 0.93 50.45
F2 1 30 − 1 3 − 1 2.5 450.1 ± 6.6 0.306 ± 0.022 − 8.27 ± 0.16 60.84
F3 − 1 10 1 9 − 1 2.5 230.1 ± 3.2 0.034 ± 0.026 − 2.95 ± 0.23 98.98
F4 1 30 1 9 − 1 2.5 369.3 ± 3.4 0.287 ± 0.028 − 3.33 ± 0.13 98.76
F5 − 1 10 − 1 3 1 7.5 324.4 ± 3.8 0.188 ± 0.009 − 9.79 ± 0.27 57.74
F6 1 30 − 1 3 1 7.5 287.8 ± 4.6 0.139 ± 0.029 − 7.84 ± 0.25 72.07
F7 − 1 10 1 9 1 7.5 177.9 ± 2.9 0.034 ± 0.030 − 3.81 ± 0.44 81.23
F8 1 30 1 9 1 7.5 223.4 ± 0.6 0.063 ± 0.007 − 3.88 ± 0.17 84.87
Axial points
F9 1.68 37 0 5 0 5 260.4 ± 1.6 0.102 ± 0.018 − 8.85 ± 0.53 66.08
F10 − 1.68 3 0 5 0 5 147.1 ± 0.7 0.032 ± 0.007 − 4.96 ± 0.17 69.52
F11 0 20 1.68 11 0 5 204.3 ± 2.5 0.081 ± 0.018 − 3.86 ± 0.27 52.84
F12 0 20 − 1.68 1 0 5 238.8 ± 0.7 0.077 ± 0.013 − 14.5 ± 0.45 55.33
F13 0 20 0 5 1.68 9.2 199.0 ± 2.1 0.071 ± 0.027 − 5.59 ± 0.19 57.27
F14 0 20 0 5 − 1.68 0.8 272.2 ± 2.1 0.103 ± 0.033 − 3.26 ± 0.19 65.65
Center points
F15 0 20 0 5 0 5 213.1 ± 0.4 0.023 ± 0.024 − 6.03 ± 0.27 72.61
F16 0 20 0 5 0 5 211.7 ± 0.3 0.034 ± 0.023 − 5.96 ± 0.16 40.92
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bag was placed on 150 ml of isotonic phosphate-buffered 
saline (PBS) 0.1  M, pH 7.4 at 37  °C. At predetermined 
intervals, 1 ml of sample was withdrawn from the stirred 
release medium and simultaneously replaced with 1  ml 
of fresh buffer at the same temperature. Akaike’s infor-
mation criteria was determined as an indicator of the 
suitability of the model for a given dataset. The model 
associated to the smallest Akaike’s information criteria 
value is considered as giving the best fit of the set of data 
[23].
Cell culture
Cells were thawed, grown, maintained and regularly 
observed under a microscope. Two cell lines were used, 
namely, mouse microvascular endothelial cells (bEnd.3) 
and astrocytes from brain rat cortex. Primary cultures of 
astrocytes were obtained from bank GAIKER-IK4 cul-
ture. The bEnd.3 cells were maintained in their specific 
culture medium, DMEM + 10% FBS [24]. Cells and cor-
responding culture medium were tempered at 37 °C, 1 ml 
of cells was diluted in 9 ml of medium and the cell sus-
pension was centrifuged at 4  °C for 5 min at a speed of 
130g. The supernatant was removed and the cells were 
re-suspended in culture medium. Cells were seeded in 
75 cm2 flasks and kept in an incubator at 37 °C, an atmos-
phere of 5%  CO2 and a relative humidity of 95%. Once 
removed and washed, the cells were seeded with fresh 
medium.
Cytotoxicity studies
Alamar blue reduction was used as a parameter for cell 
viability. This assay is based on that viable and metaboli-
cally active cells reduce resazurin to resorufin, which is 
released into the culture medium. This conversion is 
intracellular, facilitated by oxidoreductases of mitochon-
drial, microsomal and cytosolic origin. In a toxic event, 
where a loss of cell viability and proliferation occurs, the 
cells that comprise the epithelial tissue lose the ability to 
reduce resazurin. Therefore, resazurin reduction ratio 
is directly proportional to the number of viable cells. 
Absorbance was determined at λ of 570 and 620  nm, 
reduced and oxidized form, respectively [24]. Data 
were analysed by calculating the percentage of Alamar 
blue reduction and expressed as percentage of control 
(untreated), as reported before [25].
In vitro transport across the BBB
In vitro BBB models have become a standard tool for esti-
mating the ability of drugs to bypass the BBB at the early 
stage of drug development. In the present work, endothe-
lial cell-based models were optimized by co-culturing the 
endothelial cells with astrocytes in Transwell systems, 
as shown in Fig. 1. Polycarbonate transwell inserts were 
used with a semipermeable membrane of 0.4  μm pore. 
For co-culture experiments, endothelial cells were seeded 
in the apical part of the inserts. A semipermeable filter 
was placed, and in the basolateral compartment cells 
from primary cultures of rat astrocytes were added.
Trans‑epithelial electrical resistance study
The brain vasculature is characterized by endothelial cells 
with strong tight junctions that limit paracellular diffu-
sion of hydrophilic molecules selectively, according to 
their charge and size. When the movement of ions across 
the monolayer is restricted due to the proper function-
ing of the barrier, an electric potential gradient on both 
sides is generated. Transepithelial electrical resistance 
(TEER) is an indicator of cell confluence, monolayer 
integrity and the formation of tight junctions between 
cells. Thus, TEER manual measurements were taken 
daily until a steady state was reached, employing epithe-
lial EVOM2 voltmeter connected to a pair of electrodes 
STX2. The system operates with two electrodes, which 
can be applied directly to the inserts. To calculate TEER 
of each insert, Eq. (3) was used and values are expressed 
in Ω cm2.
Co-culture experiments were carried out in 24-well 
plates. Inserts were removed and placed in new media 
plates with Hanks and 0.5% bovine serum albumin (BSA). 
Apical media was removed, washed with Hanks and 
MEM–PEG–PLGA NPs were added (dissolved in 0.5% 
BSA Hanks) in the apical part of the inserts and left for 
1 h. Furthermore, to verify that MEM–PEG–PLGA NPs 
did not compromise membrane integrity, a compound 
with low paracellular permeability, Lucifer yellow (LY), 
was added at the end of the study. Membrane integrity 
(with LY) was determined calculating the permeability 
coefficient by using the clearance principle which allows 
a permeability value independent of concentration.
In vivo studies
Male APPswe/PS1dE9 (APP/PS1) and C57BL/6 mice 
were used for the in  vivo studies. APP/PS1 animals co-
express a Swedish (K594M/N595L) mutation of a chi-
meric mouse/human APP (Mo/HuAPP695swe), together 
with the human exon-9-deleted variant of PS1 (PS1-
dE9), allowing these mice to secrete elevated amounts 
of human Aβ peptide [24]. The animals were kept 
under controlled temperature, humidity and light con-
ditions with food and water provided ad  libitum. Mice 
were treated in accordance with the European Commu-
nity Council Directive 86/609/EEC and the procedures 
(3)
TEER =
[
Ωcell monolayer −ΩFilter (without cells)
]
× [Filter Surface]
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established by the Departament d’Agricultura, Ramade-
ria i Pesca of the Generalitat de Catalunya. Every effort 
was made to minimize animal suffering and to reduce the 
number of animals used. 6  month-old animals, divided 
into six groups, were used for the present study, with at 
least 10 WT and 10 APP/PS1 transgenic mice, per group. 
In each genotype group, the mice were treated either 
with untreated water, with free MEM or with MEM 
NPs (Additional file 1: Figure S1). Mice were treated for 
2  months with MEM at therapeutic dose (30  mg/kg/
day). MEM–PEG–PLGA NPs were orally administered 
in alternate days calculating the volume for each animal 
previously weighted followed by a regime of untreated 
water. After the in  vivo testing, the animals were sacri-
ficed. Prior to sacrifice, mice were left fasting for at least 
8 h and in the case of treated mice. At least 6 mice in each 
group were used for histological studies [26].
Nanoparticles brain distribution
To tackle the NPs uptake and visualize them in the target 
tissue in  vivo, MEM NPs were fluorescently labelled by 
linking PLGA to Rhodamine. NPs were orally adminis-
tered for 1 week on alternate days and after 24 h of clear-
ance mice were anesthetized with sodium pentobarbital 
and perfused with 4% paraformaldehyde. Brains were 
stored at 4  °C overnight dehydrated in 30% phosphate-
buffered sucrose solution. Samples were preserved at 
− 80  °C and coronal sections of 20  μm were obtained 
by a cryostat (Leica Microsystems, Wetzlar, Germany). 
Samples were visualized using a fluorescence microscope 
using Rhodamine filter (BX41 Laboratory Microscope, 
Melville, NY-Olympus America Inc).
Previously to the study of the therapeutic effects, drug 
at steady state levels was quantified. Blood samples were 
extracted from the facial vein and samples were centri-
fuged during 20 min at 2000 r.p.m. adding EDTA (10 μl 
 K2EDTA 18  mg/ml) to avoid blood coagulation. Mice 
were sacrificed by cervical dislocation. Amantadine was 
added as internal standard and MEM extraction was 
carried out using organic solvents (t-butyl methyl ether 
and diethyl ether–chloroform for brain and blood sam-
ples, respectively). Solvents were evaporated under 
Fig. 1 DoE of sonication parameters a surface plot of MEM‑PLGA‑PEG NPs PI and b Pareto’s chart of the effect of sonication parameters on ZP
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nitrogen flow and samples were reconstituted with 
methanol [27, 28]. Samples were analysed as described 
previously (section NPs production). The analyses were 
carried out using the parent to daughter combinations 
of m/z 180 > 163 (MEM) and m/z 152 > 135 (amantadine) 
[22].
Morris water maze
The Morris water maze (MWM) test was conducted in 
a circular tank filled with water at 21 ± 2 °C and divided 
into four equal quadrants. A white platform was sub-
merged below the water surface in the middle of the 
northeast quadrant. The behavioural data were acquired 
and analysed using a computerized video tracking sys-
tem. The procedure of the behaviour assessment con-
sisted of a six-day navigation testing session and a probe 
trail. Mice received five trials per day for 6 successive days 
continuing with the same drug regime. Animals were 
placed into the maze facing the tank wall at water-level. 
They were allowed to swim freely for 60  s to seek the 
invisible platform and allowed to remain there for 10  s. 
If a mouse failed to find the platform, it was guided to it 
and left there for 30 s. The probe trial was performed the 
day after the last training test. In the probe test, the hid-
den platform was removed, and the mice were released 
from the southwest quadrant and allowed to swim for 
60 s. Results were calculated individually for each animal 
[29].
Immunohistochemistry studies
Mice were anesthetized with sodium pentobarbital and 
perfused with 4% paraformaldehyde in 0.1 M phosphate 
buffer (PBS) after the probe trial. Brains were stored 
in 4% paraformaldehyde at 4  °C overnight then dehy-
drated in 30% phosphate-buffered sucrose solution for 
cryoprotection. Samples were preserved at − 80  °C and 
coronal sections of 20  µm were obtained by a cryostat 
(Leica Microsystems, Wetzlar, Germany). Sections were 
incubated overnight at 4  °C with the rabbit anti-GFAP 
(1:2000; Dako, Glostrup, Denmark) primary antibody, 
and sequentially incubated for 2 h with Alexa Fluor 594 
goat anti-rabbit antibody at room temperature (1:500; 
Invitrogen, Eugene, OR, USA). Staining of β-Amyloid 
plaques was performed using Thioflavin S (ThS 0.002%, 
Sigma-Aldrich) to compare β-amyloid plaque den-
sity among different treatment groups. Sections were 
counterstained with 0.1  μg/ml Hoechst 33,258 (Sigma-
Aldrich, St Louis, MO, USA) and rinsed afterwards with 
PBS 0.1  M [30]. ThS-stained β-amyloid plaques were 
visualized using a fluorescence microscope with a fluo-
rescence filter (BX41 Laboratory Microscope, Melville, 
NY-Olympus America Inc). For each image, the propor-
tion of total image area covered by fluorescently stained 
β-amyloid plaques was quantified. For each mouse, four 
fields per section with the highest density of plaques were 
chosen as representative and were averaged [31].
Statistical analysis
All of the data are presented as the mean ± S.D. Two-way 
ANOVA followed by Tukey post hoc test was performed 
for multi-group comparison. Student’s t test was used for 
two-group comparisons. Statistical significance was set at 
p < 0.05 by using GraphPad Prism version 5.00 for Win-
dows, GraphPad Software, San Diego California USA.
Results and discussion
Optimization of NPs’ parameters
Double emulsion evaporation method was chosen for 
the production of PLGA NPs due to its suitability for 
the loading of hydrophilic drugs, such as MEM. Since 
the mean particle size is a critical parameter to assure 
that NPs are absorbed in the gastrointestinal tract and 
achieve the BBB, the aim of the factorial design was to 
produce MEM–PEG–PLGA NPs with a mean size 100 
and 200  nm. Since MEM is insoluble in ethyl acetate, 
this organic solvent has been used for the preparation of 
 w1/o/w2 emulsions, allowing the retention of the drug in 
the inner aqueous phase. From preliminary studies, the 
addition of small amount of polyvinyl alcohol (PVA, 0.3%) 
after the second emulsification process was shown to 
contribute to the decrease of the mean size of NPs from 
264.6 nm (with a bimodal distribution) down to 220.1 nm 
(with a monomodal distribution, PI < 0.1). These results 
were attributed to the delay of the solvent diffusion to the 
outer aqueous phase upon addition of the aqueous PVA 
solution, limiting the risk of droplets agglutination and 
polymer precipitation [19]. The results obtained from the 
full factorial designed performed for the selection of the 
appropriate sonication parameters (i.e. wave amplitude 
and sonication time) are shown in Table 1.
Factorial design demonstrates that the interaction 
between 1st and 2nd sonication times increased the 
mean size of NPs. As a consequence, a lower 1st sonica-
tion time was chosen to obtain NPs smaller than 200 nm. 
High amplitudes, around 38%, are mandatory to obtain 
small and monodispersed NPs (Fig.  2a) [19]. As shown 
in Fig. 1b, amplitude was a significant parameter regard-
ing particles surface charge, establishing a trend where 
increasing the amplitude causes a slight increase of the 
negative charge and, subsequently, the creation of more 
stable particles. Therefore, the maximum amplitude (F9, 
Table 1) would be applied.
The optimized concentration parameters of the for-
mulation compounds have also been studied (Table  2). 
The increase of the polymer concentration caused the 
increase of both z-AVE and PI (Fig.  3a). Indeed, the 
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higher the viscosity of the inner aqueous phase of the pri-
mary emulsion  (w1/o), the less efficient is the reduction 
of the emulsion droplet size during the second emulsifi-
cation step  (w1/o/w2) [16, 17]. The higher the PVA con-
centration, the smaller the NPs obtained (Fig. 2a). These 
results suggest that the optimized PVA concentration 
should be able to ensure enough surfactant molecules 
to cover the interface between the organic phase and the 
external aqueous phase, improving the protection of the 
droplets from coalescence [17].
Pareto’s chart (Fig.  2b) shows that MEM concentra-
tion influenced the surface electrical charge of NPs sig-
nificantly. MEM has an amine group which can easily be 
protonated and decrease negative surface charge caused 
by the polymer [32, 33]. However, while high MEM 
concentrations negatively affect the particles stability, 
a statistically significant relationship between EE and 
MEM concentration was established. According to the 
factorial design data, a suitable formulation was achieved 
with a minimum concentration of polymer (10  mg/ml), 
an upper-intermediate drug concentration (9 mg/ml) and 
a maximum amount of PVA (7.5  mg/ml) (F7, Table  2). 
After ultracentrifugation at 15,000 r.p.m. for 20  min of 
the optimized formulation, NPs kept their size properties 
(z-AVE of 152.6 ± 0.5 nm and PI 0.043 ± 0.009), although 
ZP was more negative (− 22.4 ± 0.5  mV), which was 
attributed to the removal of surfactant molecules from 
the surface of the particles. Detailed structure of MEM–
PEG–PLGA NPs was further characterized by TEM, 
which confirmed the spherical shape and smooth surface 
of NPs (Additional file 1: Figure S1).
Fig. 2 DoE of concentration parameters; a surface plot of MEM –PLGA‑PEG NPs z‑AVE and b effect of compounds concentration on ZP
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Characterization of NPs and interaction studies
In vitro and in  vivo drug release profiles are highly 
dependent on the physical state of the drug inside the 
NPs. TG and DTA were therefore used to study the inter-
action between MEM and polymers. MEM shown to 
be stable at low temperatures probably due to the pres-
ence of the anhydrous [33]. TG profile of MEM exhibited 
a weight loss starting at 290  °C, and finishing at 354  °C, 
which correspond to the complete degradation of drug. 
(Additional file  1: Figure S2). DTA showed an onset of 
endothermic event at 280 °C followed by a maximum at 
352  °C being these results similar to those obtained by 
DSC. A thermal decomposition of MEM was shown to 
occur in two steps, corresponding the latter to a final oxi-
dative degradation.
DSC curves of MEM, PVA, PEG–PLGA, MEM–PEG–
PLGA NPs, and physical mixture of MEM are depicted 
in Fig.  3a. PVA exhibits two endothermic peaks, corre-
sponding to the melting (192.86  °C) and decomposition 
(318.61 °C) events, respectively. PEG-PLGA onset transi-
tion temperature  (Tg) takes place around 44.50 °C. PLGA 
without PEG chains exhibited a  Tg around 54.18 °C. The 
presence of PEG chains produced a decrease of the  Tg 
values, attributed to the plasticizing effect based on the 
reduction of the attractive forces among the polymer 
chains. MEM displayed a melting transition followed 
by decomposition between 190 and 322  °C, exhibiting a 
thermal event comprising both phenomena. DSC analy-
sis of MEM–PEG–PLGA NPs displayed an endothermic 
event corresponding to the  Tg of the polymer occurring 
at 50.56 °C. The increasing of the  Tg of the polymer has 
been attributed to the incorporation of an alkaline drug, 
which causes interactions between the carboxylic groups 
of the polymer.
Results from XRD studies are shown in Fig.  3b. Drug 
powder diffraction pattern showed sharp crystalline 
peaks, whereas PEG–PLGA showed an amorphous pro-
file. MEM–PEG–PLGA NPs displayed a profile similar as 
PEG–PLGA, but a slight attenuated peak corresponding 
to the drug was also observed. The surfactant displayed a 
semi-crystalline pattern, not present in the formulation. 
This fact demonstrates the effectiveness of the centrifu-
gation process, confirmed by FTIR analysis (Fig. 3c). This 
suggests that the surfactant acts only as adjuvant in the 
NPs production, stabilizing the freshly prepared parti-
cles while it is not entrapped in the polymer because it 
was effectively removed by centrifugation. This property 
is relevant since a high surfactant concentration may 
Fig. 3 MEM‑PLGA‑PEG NPs interaction studies a differential scanning calorimetry analysis, b X‑ray diffraction and c Fourier transformed infra‑red 
analysis
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induce toxicity by establishing an interconnected net-
work with the polymer [34].
FTIR analysis (Fig. 3c) does not show any evidence of 
chemical interaction or strong bond formation between 
MEM and PEG–PLGA or between NPs and surfactant. 
The stretching band of the polymer carbonyl groups 
(C=O) was observed at 1740 cm−1, whereas the first pol-
ymer bands are due to C–O PLGA–PEG bonds [35]. The 
bond at 2950 cm−1 clearly indicates the presence of C–H 
(ethylene glycol). PVA exhibits a number of absorption 
peaks at 2900, 1324, 843 and 1084 and 3237  cm−1 due 
to C–H stretching, C–H bending and C–O stretching, 
which are not depicted in the profile obtained for MEM–
PEG–PLGA NPs. Around 3000 cm−1 MEM showed the 
amine corresponding peak associated with N–H stretch-
ing bond. As reported by other authors, the peak at 
1648 cm−1 indicates presence of C–O group attached to 
–NH [36].
Storage stability
Stability of the developed NPs at different temperatures 
(4, 25 and 38  °C) was also monitored. Samples stored 
at 4 and 25  °C remained visually unchanged during the 
first 6  months of storage. Samples stored at 38  °C were 
completely transparent and unstable by the end of the 
1st month because of the degradation of the polymer 
induced by higher temperatures (Fig. 4a).
Fig. 4 Backscattering profile of MEM‑PLGA‑PEG NPs stored for 6 months; a 38 °C, b 25 °C and c 4 °C
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Samples stored at 4 and 25  °C kept their ZP and size 
parameters (z-AVE and PI) for 6 months. No statistically 
significant differences were found between formulations 
stored at 4 and at 25  °C. Backscattering profiles at both 
temperatures were similar to those obtained by the end 
of the 1st month, but NPs stored at 25 °C showed a slight 
decrease of the light scattered percentage corresponding 
to the bottom of the sample, which was not observed at 
4 °C (Fig. 4b, c). This result was attributed to a slight NPs 
sedimentation process being preferential the particles’ 
storage at 4 °C.
In vitro drug release
In vitro drug release was analysed against a drug solu-
tion in PBS (free MEM). Free MEM release was faster 
than the observed for MEM–PEG–PLGA NPs (Fig.  5). 
The optimized formulation showed an immediate release 
(burst release) attributed to the non-loaded MEM frac-
tion which is weakly bound to the NPs’ surface, because 
of the PEG coating [37]. After this initial phase, the 
drug displayed a sustained release diffusing slowly from 
the polymeric matrix into the release medium. Akaike’s 
information criterion for hyperbola adjustment was 64.97 
for MEM-loaded NPs and 86.8 for free drug. Parameters 
corresponding to hyperbola adjustment were analysed. 
 Kd, equilibrium dissociation constant, expressed in con-
centration, corresponding to MEM–PEG–PLGA NPs 
was almost twice (0.74 for drug loaded NPs and 0.38 for 
the free drug) than  Kd obtained for the free drug, con-
firming the slower release of the drug from the colloidal 
system.
Cytotoxicity studies
Cell viability of MEM–PEG–PLGA NPs was measured 
in bEnd.3 (brain endothelial cells) and rat astrocyte pri-
mary cultures. These cells form the BBB and, for this 
reason together they are considered as a suitable model 
to test nanoparticles cytotoxicity. Following the incuba-
tion for 24 h, MEM–PEG–PLGA NPs did not show any 
measurable toxic effect (Fig.  6). These results confirm 
that the developed particles are biocompatible with both 
endothelial glial brain cells. In addition, the slight amount 
of PVA that could remain after centrifugation process did 
not induce any toxicity nor influenced the normal growth 
of both epithelial cell lines within the assessed doses.
In vitro and in vivo transport across the BBB
Results show that 40% of the initial MEM–PEG–PLGA 
NPs were retained by the cell membrane of the in vitro 
model within 1  h of incubation, whereas only 30% of 
the initial MEM was found inside the barrier. Drug per-
meability coefficient  (Pe) in this model was 0.933. This 
fact indicates that NPs retained in this tissue would be 
able, either to achieve a slow drug release from there, 
or to partially cross through it and release the drug into 
the basolateral media. TEM images demonstrate that 
the part of MEM–PEG–PLGA NPs achieving the BBB 
remained spherical and non-aggregated with an average 
size below 200  nm (Fig.  7a). In addition, Lucifer Yellow 
(LY) was used as control at the end of the study, show-
ing that these systems do not cause disruption of the 
BBB as no increase of paracellular passage of LY was 
observed  (Pe < 1 in all the experiments). In addition, 
other authors that develop similar drug delivery systems 
for CNS diseases also demonstrate that the NPs were 
able to effectively transport the drugs. Year ago, Alyaut-
dinvand colleagues developed Polibutylcianoacrilate 
NPs encapsulating Loperamide (which is unable to pass 
through the BBB), showing that the drug delivery systems 
(around 290  nm and PI below 0.1) were effective [38]. 
More recently, Liu and co-workers developed PEGylated 
Fig. 5 In vitro release profile of MEM from PBS solution or MEM‑
PLGA‑PEG NPs. Mean parameters were obtained adjusting data to 
hyperbola equation
Fig. 6 Cell viability assessment using Alamar blue on brain cell lines
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NPs to cross the BBB with an average size smaller than 
200 nm, able to cross the BBB [39]. The author’s labelled 
the NPs fluorescently obtaining qualitative results and no 
disruption of the BBB was reported. Hereby, we provide 
behavioral and molecular data that gives solid evidence 
of the enhancement of the drug activity provided by the 
NPs [39]. In addition, spherical shape demonstrated to 
increase their transport across the BBB [40]. Moreover, 
grafting NPs with PEG decreases protein adsorption and 
slows down the nanomaterials clearance improving blood 
circulation time; as a consequence, PEGylated NPs accu-
mulate more efficiently in the brain [41].
As can be observed in Fig. 7b, Rhodamine labelled NPs 
were able to be absorbed by the GI, cross the BBB and 
reach the brain upon oral administration. Oral delivery 
is the most common route of administration and NP 
drug carriers that can shield drugs from degradation 
and deliver them enabling more efficient and sustained 
drug delivery [42]. Particles synthesized from commonly 
used polymers, such as PLGA, may achieve mucoadhe-
sion via hydrogen bonding, polymer entanglements with 
mucins, hydrophobic interactions, or a combination 
of these mechanisms [42]. The advantage that offer the 
entrapment on polymeric NPs has been demonstrated 
by several authors. For instance, Mittal et  al. developed 
similar drug delivery systems to be administered orally 
and demonstrated their ability to be absorbed by the 
GI and provide therapeutic blood levels [43]. It has also 
been demonstrated that, in addition of NPs size, the sol-
vent and the stabilized used has an effect on drug release. 
Other authors, such as Sahana and co-workers develop 
similar drug delivery systems with a mean size around 
270  nm using ethyl acetate and PVA obtaining a pro-
longed drug release for 3 days after their administration 
and Kalaria and collegues also achieve superior effectivity 
of oral PLGA NPs compared with the free drug in  vivo 
[44, 45]. Moreover, NP surface characteristics can be tai-
lored to optimize mucoadhesion [42]. As demonstrated 
by Tobío and co-workers, PEGylation of polymeric NPs 
of a mena size around 160  nm, imparts additional pro-
tection against enzyme induced aggregation and deg-
radation in simulated GI fluids in  vitro [46]. Previous 
publications of our group demonstrated that PLGA 
PEGylated NPs were suitable for GI absortion [47] show-
ing the NPs groups and increased behavioral and molec-
ular effectivity.
In addition, NPs demonstrated to be able to reach the 
hippocampus confirming that this drug delivery systems 
could be an effective strategy to achieve an increased 
drug release. Furthermore, plasma levels after a single 
NPs dose were recorded achieving MEM concentrations 
in plasma around 883.02 ng/ml after 40 h of clearance.
Morris water maze test
The effects of MEM treatment on the animal’s behaviour 
were assessed with the MWM test (Fig.  8). The overall 
ANOVA for the training days revealed both a genotype 
(APP/PS1 against WT showed significant differences, 
p < 0.01) and a drug effect (treated vs untreated APP/PS1 
mice) on mice spatial learning capacities. Escape latency 
on the test day results are shown in Fig.  8a. Untreated 
APP mice showed a significant increase on scape latency 
compared to MEM loaded NPs group (p  < 0.01). In addi-
tion, mice treated with NPs revealed an improvement on 
spatial learning memory compared with free MEM (no 
statistically significant differences). This indicates that 
the developed nanosystems constitute a suitable strategy 
for the delivery of drugs for AD.
As shown in Fig.  8b, MEM-loaded NPs groups fol-
lowed a more direct path until platform, than the rest of 
transgenic groups. As expected, significant differences 
were obtained with APP/PS1 untreated group and MEM-
loaded NPs (p < 0.01). Regarding time percentage in the 
platform quadrant (data not shown), APP/PS1 mice 
treated with MEM-loaded NPs presented an average 
Fig. 7 a TEM pictures of MEM–PEG–PLGA NPs on the basolateral 
compartment of the BBB transport model after one hour of incuba‑
tion, b Hipocampus of WT mice with PLGA‑Rho NPs
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of 37.22% of the time, whereas transgenic mice treated 
with MEM spend a 24.72% of the time revealing that oral 
MEM-loaded NPs restore cognition more effectively than 
the free drug.
Immunohistochemistry
The formation of Aβ plaques, which is a pathologic hall-
mark of AD, could be observed by Thioflavin˗S staining. 
Several studies confirmed that MEM decrease the num-
ber of amyloid plaques, therefore, histological studies to 
observe plaque development would be of great relevance. 
Figure  9a shows the results corresponding to amyloid 
plaques counting of APP/PS1 mice. WT groups did 
not develop β-amyloid plaques. APP/PS1 mice treated 
with NPs developed some plaques, but the number was 
significantly lower than those obtained for the rest of 
transgenic groups (p < 0.001 against untreated mice and 
p < 0.01 against MEM mice).
Figure 9b depicts the microscopic images after immu-
nohistochemically staining of insoluble β-plaque devel-
opment. APP untreated mice showed a greater plaque 
development. Moreover, plaques were surrounded by 
a high inflammatory state characteristic of AD. MEM–
PEG–PLGA NPs groups showed fewer plaques and also 
inflammation degree was lower than the rest of trans-
genic groups [48]. These results are in agreement with 
behavioural assays, indicating that MEM restored cog-
nition by decreasing insoluble amyloid plaques and the 
inflammatory response associated with AD.
Conclusions
In this study, factorial design allowed to obtain NPs with 
an average size lower than 200 nm and PI < 0.1, character-
istic of monodispersed systems, suitable to be absorbed 
by the gastrointestinal tract and release the drug across 
the BBB. The optimized formulation was obtained by 
adding 7.5  mg/ml of surfactant, a low polymer concen-
tration and a high drug amount. NPs were washed by 
ultracentrifugation process and effective surfactant elimi-
nation was demonstrated both by XRD and FTIR since 
no PVA bands were observed in the NPs profile. This sug-
gests that the surfactant only acts as an adjuvant in the 
Fig. 8 Morris water maze results on the probe trail of the APP/PS1 mice. a Escape latency and b representative swimming path of transgenic mice. 
Data represent mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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NPs production, stabilizing the colloidal suspension and 
it is not entrapped in the polymer since it was effectively 
removed by centrifugation. This is an increase outcome 
since a high surfactant amount may induce toxicity by 
establishing an interconnected network with the polymer. 
MEM–PEG–PLGA NPs raised the  Tg of the polymer, 
thus confirming the drug loading within the particles. 
Moreover, no evidence of strong bond or chemical inter-
action between drug and polymer was found. MEM–
PEG–PLGA NPs did not show the drug melting and 
decomposition process observed in the physical mixture, 
confirming that the drug loaded into NPs was in the form 
of either a molecular dispersion or in a solid solution.
MEM–PEG–PLGA NPs showed to be physically sta-
ble upon 6  months storage both at 25 and 4  °C, being 
preferable 4  °C storage due to a slight NPs sedimenta-
tion process observed in the backscattering profile. The 
developed formulation presented a slow in  vitro release 
profile at 37 °C against free drug both fitting to hyperbola 
equation. This could be due to a first fast drug release 
(burst effect) provided by the drug accumulated onto the 
NPs surface, followed by a released caused by the drug 
entrapped into the polymeric matrix.
The in  vitro and in  vivo results for brain drug levels 
showed clear evidence that the developed systems provide 
a sustained delivery of the drug into the target tissue. The 
developed colloidal systems increase drug amount into 
the target organ and confirm the suitability of the NPs for 
oral administration attributed to the bioadhesive polymer 
properties. Moreover, reduced administration frequency 
(on alternate days) demonstrated to be adequate to 
achieve brain therapeutic concentrations of drug. Behav-
ioural and histological studies of APP/PS1 and WT mice 
treated with NPs in alternate days showed a better effect 
of NPs groups against free MEM treatment improving 
both learning capacities and β-amyloid brain plaques on 
APP/PS1 animals. This can be attributed to the sustained 
release obtained with MEM–PEG–PLGA NPs that pro-
vide a stable drug amount into the target organ.
In summary, MEM–PEG–PLGA NPs could be a 
promising alternative towards a better treatment of AD 
patients since NPs have demonstrated to be capable to 
provide a more effective treatment than free MEM.
Abbreviations
AD: Alzheimer’s disease; Aβ: β‑amyloid; MEM: memantine; PLGA: 
poly(lactic‑co‑glycolic acid); FDA: Food and Drug Administration; NPs: 
nanoparticles; PEG: poly(ethylene glycol); PVA: polyvinyl alcohol; Z‑AVE: mean 
average size; PI: polydispersity index; ZP: zeta potential; EE: encapsulation 
efficiency; TEM: transmission electron microscopy; Pe: permeability across cell 
monolayer; APP/PS1: APPswe/PS1dE9 mice.
Additional file
Additional file 1: Figure S1. MEM‑PLGA‑PEG NPs transmission electron 
microscopy and size distribution obtained by dynamic light scattering. 
Figure S2. MEM thermogravimetric and differential thermal analysis. Fig-
ure S3. A) Experimental groups involved on the study, B) In vivo Timeline. 
Figure S4. Escape latency results of the Morris water maze test on the 
probe trail of the WT mice.
Fig. 9 a Immunohistochemically (cortex) staining of amyloid plaques (green) and GFAP (red) of WT and APP/PS1 mice (untreated, MEM free and 
MEM loaded NPs). Bar reference equivalent to 100 µm. and b Amyloid plaques counting of APP/PS1 mice. Data represent mean ± SD; *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001
Page 15 of 16Sánchez‑López et al. J Nanobiotechnol  (2018) 16:32 
Authors’ contributions
ESL developed, participate and coordinate the experiments carried out in 
this study. ME undertake the immunohistochemistry experiments, assist 
and conduct the animal behavioral tests, MAE and ME help to analyze and 
interpret the physicochemical characterization of the nanoparticles, AC attach 
covalently the Rhodamine to the polymer and assist ESL during the micro‑
scopic studies. ACC interpret the in vitro drug release, AC supervise the in vivo 
animal experiments, NC collaborate on the development, production and 
animal behavioral tests, AMS and EBS assist and interpret the in vitro cellular 
experiments as well as revising the English throughout the Manuscript, MLG 
supervise all the experiments and edit the final version of the Manuscript. All 
authors read and approved the final manuscript.
Author details
1 Department of Pharmacy, Pharmaceutical Technology and Physical Chem‑
istry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain. 
2 Institute of Nanoscience and Nanotechnology (IN2UB), Faculty of Pharmacy, 
University of Barcelona, 08028 Barcelona, Spain. 3 Networking Research 
Centre of Neurodegenerative Disease (CIBERNED), Instituto de Salud Juan 
Carlos III, Madrid, Spain. 4 Department of Pharmacology and Therapeutic 
Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, 
Spain. 5 Department of Biology and Environment, School of Life and Envi‑
ronmental Sciences (ECVA, UTAD), University of Trás‑os‑Montes and Alto 
Douro, Quinta de Prados, 5001‑801 Vila Real, Portugal. 6 Centre for Research 
and Technology of Agro‑Environmental and Biological Sciences, University 
of Trás‑os‑Montes and Alto Douro, CITAB‑UTAD, 5001‑801 Vila Real, Portugal. 
7 Department of Pharmaceutical Technology, Faculty of Pharmacy, University 
of Coimbra (FFUC), Polo das Ciencias da Saúde Azinhaga de Santa Comba, 
3000‑548 Coimbra, Portugal. 8 REQUIMTE/LAQV, Group of Pharmaceutical 
Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal. 
Acknowledgements
The author’s would like to acknowledge the Spanish Ministry of Science and 
Innovation for the financial support and David Bellido from the serveis cientif‑
ico‑tècnics for it’s assistance during HPLC/MS/MS memantine quantification.
Competing interests
The authors declare that they have no competing interests
Availability of data and materials
Not applicable.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All the experiments were approved by the Ethic committee of the University 
of Barcelona. In addition, mice were treated in accordance with the European 
Community Council Directive 86/609/EEC and the procedures established by 
the Departament d’Agricultura, Ramaderia I Pesca of the Generalitat de Catalunya.
Funding
This work was supported by the Spanish Ministry of Science and Innovation 
(MAT 2014‑59134‑R projects). MLG, ACC, ME, MAE and ESL belong to 2014SGR‑
1023 and AC and ME belong to 2014SGR 525. The first author, ESL, acknowl‑
edges the support of the Spanish Ministry for the PhD scholarship FPI‑MICINN 
(BES‑2012‑056083) and Agustí Pere i Pons Institution. We also acknowledge 
the Portuguese Foundation for Science and Technology under the projects 
M‑ERA‑NET‑0004/2015, UID/AGR/04033/2013 and UID/QUI/50006/2013, 
receiving financial support from FCT/MEC through national funds, and co‑
financed by FEDER, under the Partnership Agreement PT2020.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 11 October 2017   Accepted: 19 March 2018
References
 1. Nakamura Y, Kitamura S, Homma A, Shiosakai K, Matsui D. Efficacy and 
safety of memantine in patients with moderate‑to‑severe Alzheimer’s 
disease: results of a pooled analysis of two randomized, double‑
blind, placebo‑controlled trials in Japan. Exp Opin Pharmacother. 
2014;15(7):913–25.
 2. Cacciatore I, Ciulla M, Fornasari E, Marinelli L, Di Stefano A. Solid lipid 
nanoparticles as a drug delivery system for the treatment of neurodegen‑
erative diseases. Exp Opin Drug Deliv. 2016;5247:1–11.
 3. Gamisans F, Lacoulonche F, Chauvet A, Espina M, Garcı́a M, Egea M. 
Flurbiprofen‑loaded nanospheres: analysis of the matrix structure by 
thermal methods. Int J Pharm. 1999;179(1):37–48.
 4. Calvo P, Gouritin B, Angelo JD, Noel J, Georgin D, Fattal E, et al. Long‑circu‑
lating PEGylated polycyanoacrylate nanoparticles as new drug carrier for 
brain delivery. Pharm Res. 2001;18(8):1157–66.
 5. Cai Q, Wang L, Deng G, Liu J, Chen Q, Chen Z. Systemic delivery to central 
nervous system by engineered PLGA nanoparticles. Am J Transl Res. 
2016;8(2):749–64.
 6. Jose S, Sowmya S, Cinu TA, Aleykutty NA, Thomas S, Souto EB. Surface 
modified PLGA nanoparticles for brain targeting of Bacoside‑A. Eur J 
Pharm Sci. 2014;63:29–35. https://doi.org/10.1016/j.ejps.2014.06.024.
 7. Xu Y, Kim CS, Saylor DM, Koo D. Polymer degradation and drug delivery 
in PLGA‑based drug—polymer applications: a review of experiments and 
theories. J Biomed Mater Res Part B Appl Biomater. 2017;105(6):1692–716.
 8. Fornaguera C, Feiner‑Gracia N, Calderó G, García‑Celma MJ, Solans C. 
Galantamine‑loaded PLGA nanoparticles, from nano‑emulsion templat‑
ing, as novel advanced drug delivery systems to treat neurodegenerative 
diseases. Nanoscale. 2015;7(28):12076–84.
 9. Huo ZJ, Wang SJ, Wang ZQ, Zuo WS, Liu P, Pang B, et al. Novel nanosystem 
to enhance the antitumor activity of lapatinib in breast cancer treatment: 
therapeutic efficacy evaluation. Cancer Sci. 2015;106(10):1429–37.
 10. Cruz LJ, Stammes MA, Que I, Van Beek ER, Knol‑Blankevoort VT, Snoeks 
TJA, et al. Effect of PLGA NP size on efficiency to target traumatic brain 
injury. J Control Release. 2016;223:31–41.
 11. Kurz A, Grimmer T. Efficacy of memantine hydrochloride once‑daily in 
Alzheimer’s disease. Exp Opin Pharmacother. 2014;15(13):1955–60.
 12. Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzhei‑
mer’s disease: a systematic review and meta‑analysis. PLoS ONE. 
2015;10(4):1–16.
 13. Joshi G, Kumar A, Sawant K. Enhanced bioavailability and intestinal 
uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery. 
Eur J Pharm Sci. 2014;60:80–9.
 14. Zhu S, Chen S, Gao Y, Guo F, Li F, Xie B, et al. Enhanced oral bioavail‑
ability of insulin using PLGA nanoparticles co‑modified with cell‑
penetrating peptides and Engrailed secretion peptide. Drug Deliv. 
2016;23(6):1980–91.
 15. Inchaurraga L, Martín‑Arbella N, Zabaleta V, Quincoces G, Peñuelas 
I, Irache JM. In vivo study of the mucus‑permeating properties of 
PEG‑coated nanoparticles following oral administration. Eur J Pharm 
Biopharm. 2015;97:280–9.
 16. Meng FT, Ma GH, Qiu W, Su ZG. W/O/W double emulsion technique 
using ethyl acetate as organic solvent: effects of its diffusion rate on the 
characteristics of microparticles. J Control Release. 2003;91(3):407–16.
 17. Lamprecht A, Ubrich N, Hombreiro Pérez M, Lehr C‑M, Hoffman M, Main‑
cent P. Influences of process parameters on nanoparticle preparation 
performed by a double emulsion pressure homogenization technique. 
Int J Pharm. 2000;196(2):177–82.
 18. Zambaux M. Influence of experimental parameters on the characteristics 
of poly(lactic acid) nanoparticles prepared by a double emulsion method. 
J Control Release. 1998;50(1–3):31–40.
 19. Bilati U, Allémann E, Doelker E. Sonication parameters for the preparation 
of biodegradable nanocapsules of controlled size by the double emul‑
sion method. Pharm Dev Technol. 2003;8(1):1–9.
 20. Abrego G, Alvarado HL, Egea MA, Gonzalez‑Mira E, Calpena AC, Garcia 
ML. Design of nanosuspensions and freeze‑dried PLGA nanoparticles as 
a novel approach for ophthalmic delivery of pranoprofen. J Pharm Sci. 
2014;103(10):3153–64.
 21. Andreani T, Miziara L, Lorenzón EN, De Souza ALR, Kiill CP, Fangueiro JF, 
et al. Effect of mucoadhesive polymers on the in vitro performance of 
insulin‑loaded silica nanoparticles: interactions with mucin and biomem‑
brane models. Eur J Pharm Biopharm. 2015;93:118–26.
Page 16 of 16Sánchez‑López et al. J Nanobiotechnol  (2018) 16:32 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 22. Almeida AA, Campos DR, Bernasconi G, Calafatti S, Barros FAP, Eberlin 
MN, et al. Determination of memantine in human plasma by liquid chro‑
matography–electrospray tandem mass spectrometry: application to a 
bioequivalence study. J Chromatogr B. 2007;848:311–6.
 23. Abrego G, Alvarado H, Souto EB, Guevara B, Halbaut L, Parra A, et al. 
Biopharmaceutical profile of pranoprofen‑loaded PLGA nanoparticles 
containing hydrogels for ocular administration. Eur J Pharm Biopharm. 
2015;231:1–10.
 24. Andreani T, Kiill CP, de Souza ALR, Fangueiro JF, Fernandes L, Doktorovová 
S, et al. Surface engineering of silica nanoparticles for oral insulin delivery: 
characterization and cell toxicity studies. Colloids Surf B Biointerfaces. 
2014;123:916–23.
 25. Fangueiro JF, Andreani T, Egea MA, Garcia ML, Souto SB, Silva AM, et al. 
Design of cationic lipid nanoparticles for ocular delivery: development, 
characterization and cytotoxicity. Int J Pharm. 2014;461(1–2):64–73.
 26. Pedrós I, Petrov D, Allgaier M, Sureda F, Barroso E, Beas‑Zarate C, et al. 
Early alterations in energy metabolism in the hippocampus of APPswe/
PS1dE9 mouse model of Alzheimer’s disease. Biochim Biophys Acta Mol 
Basis Dis. 2014;1842(9):1556–66.
 27. Nagakura A, Shitaka Y, Yarimizu J, Matsuoka N. Characterization of 
cognitive deficits in a transgenic mouse model of Alzheimer’s dis‑
ease and effects of donepezil and memantine. Eur J Pharmacol. 
2013;703(1–3):53–61.
 28. Steuer H, Jaworski A, Elger B, Kaussmann M, Keldenich J, Schneider H, 
et al. Functional characterization and comparison of the outer blood‑
retina barrier and the blood–brain barrier. IOVS. 2005;46(3):1047–53.
 29. Zhang C, Wan X, Zheng X, Shao X, Liu Q, Zhang Q, et al. Dual‑functional 
nanoparticles targeting amyloid plaques in the brains of Alzheimer’s 
disease mice. Biomaterials. 2014;35(1):456–65.
 30. Porquet D, Andrés‑Benito P, Griñán‑Ferré C, Camins A, Ferrer I, Canudas 
AM, et al. Amyloid and tau pathology of familial Alzheimer’s disease APP/
PS1 mouse model in a senescence phenotype background (SAMP8). Age 
(Omaha). 2015;37(12):1–17.
 31. Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AHL, Baum L. Highly 
stabilized curcumin nanoparticles tested in an in vitro blood–brain 
barrier model and in Alzheimer’s disease Tg2576 mice. AAPS J. 
2013;15(2):324–36.
 32. Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer’s disease and 
other neurodegenerative disorders—memantine, a new hope. Pharma‑
col Res. 2005;51(1):1–17.
 33. Vega E, Egea MA, Calpena AC, Espina M, García ML. Role of 
hydroxypropyl‑β‑cyclodextrin on freeze‑dried and gamma‑irradiated 
PLGA and PLGA–PEG diblock copolymer nanospheres for ophthalmic 
flurbiprofen delivery. Int J Nanomed. 2012;7:1357–71.
 34. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl 
alcohol associated with poly (d, l‑lactide‑co‑glycolide) nanoparticles 
affects their physical properties and cellular uptake. J Control Release. 
2002;82(1):105–14.
 35. Parra A, Mallandrich M, Clares B, Egea MA, Espina M, García ML, et al. 
Design and elaboration of freeze‑dried PLGA nanoparticles for the 
transcorneal permeation of carprofen: ocular anti‑inflammatory applica‑
tions. Colloids Surf B Biointerfaces. 2015;136:935–43.
 36. Lokhande MV, Kumar Gupta M, Rathod NG. Structural elucidation of pro‑
cess related impurity in memantine hydrochloride bulk drug by GCMS, 
NMR and IR techniques. Int J Med Pharm Sci. 2013;3(3):107–14.
 37. Gajendiran M, Gopi V, Elangovan V, Murali RV, Balasubramanian S. 
Isoniazid loaded core shell nanoparticles derived from PLGA–PEG–PLGA 
tri‑block copolymers: in vitro and in vivo drug release. Colloids Surf B 
Biointerfaces. 2013;104:107–15.
 38. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter 
J. Delivery of Loperamide across the Blood–brain barrier with poly‑
sorbate 80‑coated Polybutylcyanoacrilate nanoparticles. Pharm Res. 
1997;14(3):325–8.
 39. Liu L, Guo K, Lu J, Venkatraman SS, Luo D, Ng KC, et al. Biologically active 
core/shell nanoparticles self‑assembled from cholesterol‑terminated 
PEG‑TAT for drug delivery across the blood‑brain barrier. Biomaterials. 
2008;29(10):1509–17.
 40. Fong CW. Permeability of the blood–brain barrier: molecular mecha‑
nism of transport of drugs and physiologically important compounds. J 
Membr Biol. 2015;248(4):651–69.
 41. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparti‑
cle‑mediated brain drug delivery: overcoming blood‑brain barrier to treat 
neurodegenerative diseases. J Control Release. 2016;235:34–47.
 42. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nano‑
particles: The gastrointestinal mucus barriers. Adv Drug Deliv Rev. 
2012;64(6):557–70. https://doi.org/10.1016/j.addr.2011.12.009.
 43. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MNV. Estradiol loaded PLGA 
nanoparticles for oral administration: effect of polymer molecular weight 
and copolymer composition on release behavior in vitro and in vivo. J 
Control Release. 2007;119(1):77–85.
 44. Sahana DK, Mittal G, Bhardwaj V, Kumar MNVR. PLGA nanoparticles for 
oral delivery of hydrophobic drugs: influence of organic solvent on nano‑
particle formation and release behavior in vitro and in vivo using Estradiol 
as a model drug. J Pharm Sci. 2008;97(4):1530–42.
 45. Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MN. Design of biodegradable 
nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics 
and toxicity studies in rats. Pharm Res. 2009;26(3):492–501.
 46. Tobı́o M, Sánchez A, Vila A, Soriano I, Evora C, Vila‑Jato J, et al. The role of 
PEG on the stability in digestive fluids and in vivo fate of PEG‑PLA nano‑
particles following oral administration. Colloids Surfaces B Biointerfaces. 
2000;18(3–4):315–23.
 47. Sánchez‑López E, Ettcheto M, Egea MA, Espina M, Calpena AC, Folch 
J, et al. New potential strategies for Alzheimer’s disease prevention: 
pegylated biodegradable dexibuprofen nanospheres administration to 
APPswe/PS1dE9. Nanomed Nanotechnol Biol Med. 2016;13:1171–82.
 48. Valles SL, Dolz‑Gaiton P, Gambini J, Borras C, Lloret A, Pallardo FV, et al. 
Estradiol or genistein prevent Alzheimer’s disease‑associated inflamma‑
tion correlating with an increase PPAR gamma expression in cultured 
astrocytes. Brain Res. 2010;1312:138–44.
